Cardiff Oncology Stock Price Prediction

CRDF Stock  USD 4.03  0.06  1.51%   
As of 1st of February 2025, the RSI of Cardiff Oncology's share price is approaching 44 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Cardiff Oncology, making its price go up or down.

Oversold Vs Overbought

44

 
Oversold
 
Overbought
The successful prediction of Cardiff Oncology's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Cardiff Oncology and does not consider all of the tangible or intangible factors available from Cardiff Oncology's fundamental data. We analyze noise-free headlines and recent hype associated with Cardiff Oncology, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Cardiff Oncology's stock price prediction:
EPS Estimate Next Quarter
(0.25)
EPS Estimate Current Year
(0.99)
EPS Estimate Next Year
(1.02)
Wall Street Target Price
10.75
EPS Estimate Current Quarter
(0.27)
Using Cardiff Oncology hype-based prediction, you can estimate the value of Cardiff Oncology from the perspective of Cardiff Oncology response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Cardiff Oncology using Cardiff Oncology's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Cardiff using crowd psychology based on the activity and movement of Cardiff Oncology's stock price.

Cardiff Oncology Implied Volatility

    
  2.58  
Cardiff Oncology's implied volatility exposes the market's sentiment of Cardiff Oncology stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cardiff Oncology's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cardiff Oncology stock will not fluctuate a lot when Cardiff Oncology's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Cardiff Oncology to buy its stock at a price that has no basis in reality. In that case, they are not buying Cardiff because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Cardiff Oncology after-hype prediction price

    
  USD 4.02  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.

Prediction based on Rule 16 of the current Cardiff contract

Based on the Rule 16, the options market is currently suggesting that Cardiff Oncology will have an average daily up or down price movement of about 0.16% per day over the life of the 2025-03-21 option contract. With Cardiff Oncology trading at USD 4.03, that is roughly USD 0.006498 . If you think that the market is fully incorporating Cardiff Oncology's daily price movement you should consider acquiring Cardiff Oncology options at the current volatility level of 2.58%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Check out Cardiff Oncology Basic Forecasting Models to cross-verify your projections.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiff Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.285.5316.29
Details
Naive
Forecast
LowNextHigh
0.14.9215.68
Details
5 Analysts
Consensus
LowTargetHigh
9.7810.7511.93
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.31-0.25-0.21
Details

Cardiff Oncology After-Hype Price Prediction Density Analysis

As far as predicting the price of Cardiff Oncology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cardiff Oncology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cardiff Oncology, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Cardiff Oncology Estimiated After-Hype Price Volatility

In the context of predicting Cardiff Oncology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cardiff Oncology's historical news coverage. Cardiff Oncology's after-hype downside and upside margins for the prediction period are 0.20 and 14.78, respectively. We have considered Cardiff Oncology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
4.03
4.02
After-hype Price
14.78
Upside
Cardiff Oncology is very risky at this time. Analysis and calculation of next after-hype price of Cardiff Oncology is based on 3 months time horizon.

Cardiff Oncology Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Cardiff Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardiff Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cardiff Oncology, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.62 
10.76
  0.01 
  0.04 
6 Events / Month
14 Events / Month
In about 6 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
4.03
4.02
0.25 
53,800  
Notes

Cardiff Oncology Hype Timeline

Cardiff Oncology is currently traded for 4.03. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.04. Cardiff is forecasted to decline in value after the next headline, with the price expected to drop to 4.02. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.25%, whereas the daily expected return is currently at 0.62%. The volatility of related hype on Cardiff Oncology is about 14924.66%, with the expected price after the next announcement by competition of 3.99. About 27.0% of the company shares are held by institutions such as insurance companies. The book value of Cardiff Oncology was currently reported as 1.01. The company recorded a loss per share of 0.95. Cardiff Oncology last dividend was issued on the 20th of February 2019. The entity had 1:6 split on the 20th of February 2019. Given the investment horizon of 90 days the next forecasted press release will be in about 6 days.
Check out Cardiff Oncology Basic Forecasting Models to cross-verify your projections.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

Cardiff Oncology Related Hype Analysis

Having access to credible news sources related to Cardiff Oncology's direct competition is more important than ever and may enhance your ability to predict Cardiff Oncology's future price movements. Getting to know how Cardiff Oncology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cardiff Oncology may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
RVPHReviva Pharmaceuticals Holdings(0.37)7 per month 8.21  0.11  18.87 (11.88) 71.13 
EFTREffector Therapeutics(0.06)4 per month 0.00 (0.31) 8.70 (27.78) 88.91 
PDSBPDS Biotechnology Corp 0.16 6 per month 0.00 (0.17) 8.37 (10.12) 24.25 
NAVBNavidea Biopharmaceuticals 0.00 0 per month 0.00 (0.14) 12.50 (12.50) 40.40 
RVPHWReviva Pharmaceuticals Holdings 0.01 4 per month 15.93  0.12  29.41 (23.33) 135.71 
EYENEyenovia(0.01)10 per month 0.00 (0.17) 19.05 (23.37) 81.46 
CGTXCognition Therapeutics 0.00 8 per month 4.56  0.08  13.95 (9.80) 39.60 
RNAZTranscode Therapeutics(1.52)8 per month 0.00 (0.07) 13.07 (12.12) 73.09 
KODKodiak Sciences 1.23 8 per month 5.28  0.17  11.39 (9.57) 45.02 
SLSSellas Life Sciences(0.04)7 per month 5.39  0.06  8.60 (9.52) 56.63 
NLSPNLS Pharmaceutics AG 0.13 5 per month 0.00 (0.09) 16.99 (11.28) 71.88 
MREOMereo BioPharma Group(0.34)7 per month 0.00 (0.15) 6.16 (7.59) 20.77 
ARAVAravive(0.17)1 per month 0.00 (0.06) 7.14 (7.83) 26.51 
DAWNDay One Biopharmaceuticals(0.21)8 per month 0.00 (0.09) 4.00 (3.46) 11.05 
INABIn8bio Inc(0.01)5 per month 0.00 (0.03) 11.54 (10.81) 36.85 
CUECue Biopharma 0.04 8 per month 6.50  0  14.88 (11.26) 38.78 
LTRNLantern Pharma(0.06)8 per month 5.07  0.09  13.33 (8.59) 44.50 
GRCLGracell Biotechnologies 0.00 0 per month 6.35  0.16  16.34 (6.25) 52.11 
CGEMCullinan Oncology LLC(0.34)10 per month 0.00 (0.16) 5.13 (7.10) 17.21 
BOLTBolt Biotherapeutics 0.00 7 per month 0.00 (0.14) 5.00 (6.45) 16.07 
LYRALyra Therapeutics(0.02)4 per month 0.00 (0.06) 8.00 (10.00) 36.57 
AUTLAutolus Therapeutics(0.01)9 per month 0.00 (0.21) 6.02 (7.83) 21.68 

Cardiff Oncology Additional Predictive Modules

Most predictive techniques to examine Cardiff price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cardiff using various technical indicators. When you analyze Cardiff charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Cardiff Oncology Predictive Indicators

The successful prediction of Cardiff Oncology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cardiff Oncology, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cardiff Oncology based on analysis of Cardiff Oncology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cardiff Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cardiff Oncology's related companies.
 2022 2024 2025 (projected)
Dividend Yield0.0067820.00780.00741
Price To Sales Ratio158.13121.95201.15

Story Coverage note for Cardiff Oncology

The number of cover stories for Cardiff Oncology depends on current market conditions and Cardiff Oncology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cardiff Oncology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cardiff Oncology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Cardiff Oncology Short Properties

Cardiff Oncology's future price predictability will typically decrease when Cardiff Oncology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cardiff Oncology often depends not only on the future outlook of the potential Cardiff Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cardiff Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding44.7 M
Cash And Short Term Investments74.8 M

Complementary Tools for Cardiff Stock analysis

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Transaction History
View history of all your transactions and understand their impact on performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios